Steen Klysner

Steen Klysner

Company: Amarna Therapeutics

Job title: Chief Executive Officer


Circumventing Immunogenicity in Gene Therapy With Svec, a Novel SV40 Based Viral Vector Platform 1:30 pm

The crucial role of immunity and tolerance in gene therapy Features and development of the SVec platform in Haemophilia Opening new frontiers in gene therapy: Potential to restore tolerance in autoimmunityRead more

day: Day 2 Track 1 PM

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.